<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370095</url>
  </required_header>
  <id_info>
    <org_study_id>14-0490</org_study_id>
    <nct_id>NCT02370095</nct_id>
  </id_info>
  <brief_title>Treprostinil Sodium Inhalation for Patients At High Risk for ARDS</brief_title>
  <official_title>Treprostinil Sodium Inhalation for Patients At High Risk for ARDS: Effect on Oxygenation and Disease-related Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Respiratory Distress Syndrome (ARDS) is a rapidly progressing lung disease caused by a
      number of factors including pneumonia, sepsis and acute trauma that leads to reduced lung
      function and breathlessness. There are no pharmacological treatments approved for the
      treatment of ARDS. This pilot trial will study the safety and efficacy of Treprostinil sodium
      by inhalation for preventing the progression of acute hypoxemic respiratory failure to
      positive pressure ventilation and/or ARDS in patients at high risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ARDS is defined by acute hypoxemia, respiratory failure and the presence of bilateral lung
      infiltrates. ARDS is a syndrome of inflammation and increased permeability that may coexist
      with left atrial or pulmonary capillary hypertension. Several recent trials in ARDS / ALI
      (Acute Lung Injury) have generated interest in the use of Prostacyclin (PGI2) and
      prostacyclin analogs in improving oxygenation in ARDS / ALI. PGI2 is an arachidonic acid
      metabolite naturally produced in the lung by endothelial cells, dendritic cells, smooth
      muscle cells and fibroblasts. PGI2 is a potent selective pulmonary vasodilator and inhibitor
      of platelet aggregation. The cellular effects include smooth muscle relaxation, inhibition of
      cell migration, decreased dextran permeability in epithelial cell cultures in vitro,
      decreased high tidal volume mechanical ventilation injury in mice and inhibition of
      fibroblast adhesion and differentiation. PGI2 has broad anti-inflammatory activity,
      inhibiting the production of Tumor necrosis factor alpha (TNFα), interleukin 1 beta (IL-1β),
      interleukin 6 (IL-6) and granulocyte macrophage colony-stimulating factor (GMCSF) in human
      alveolar macrophages.

      The study objectives are:

        1. To assess the feasibility of a randomized trial of treprostinil inhalation in patients
           with acute hypoxemic respiratory failure not requiring positive pressure ventilation.

        2. To evaluate the tolerability of inhaled treprostinil for patients with acute hypoxemic
           respiratory failure

        3. To assess the effect of treprostinil inhalation on oxygenation in patients with acute
           hypoxic respiratory failure with, or at risk for, development of ARDS

        4. To assess the effect of treprostinil inhalation on various biomarkers thought to be
           related to the pathogenesis and/or clinical course of ARDS.

      The hypothesis is: Treprostinil solution for inhalation (TYVASO) is safe and will improve
      oxygenation and other secondary outcomes related to acute hypoxemic respiratory failure and
      positive pressure ventilation initiation and duration, as well as exhibit effects on
      ARDS-related pro-inflammatory and pro-fibrotic biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 7, 2017</completion_date>
  <primary_completion_date type="Actual">October 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Ratio of the Partial Pressure of Arterial Oxygen to the Fraction of Inspired Oxygen (PaO2/FiO2 Ratio)</measure>
    <time_frame>Change in PaO2/FiO2 ratio from day 0 to day 2.</time_frame>
    <description>PaO2/FiO2 ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Ratio of Peripheral Oxygen Saturation to Fraction of Inspired Oxygen (SaO2/FiO2)</measure>
    <time_frame>0-12 days</time_frame>
    <description>SaO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Not on a Ventilator</measure>
    <time_frame>0-28 days post enrollment</time_frame>
    <description>Ventilator-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Required Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) Via Face Mask</measure>
    <time_frame>0-28 days</time_frame>
    <description>BiPAP / CPAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Respiratory Distress Syndrome (ARDS) Associated Biomarkers</measure>
    <time_frame>Change from day 0 on days 3 and 7</time_frame>
    <description>Change in ARDS associated plasma biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Central Venous Oxygen Saturation (SCVO2).</measure>
    <time_frame>Change in SCVO2 from Day 0 to 3 (if central venous catheter in place)</time_frame>
    <description>SCVO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Venous Pressure (CVP).</measure>
    <time_frame>Change in CVP from Day 0 to 3 (if central venous catheter in place)</time_frame>
    <description>CVP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Arterial Pressure (MAP).</measure>
    <time_frame>Change in MAP from Day 0 to day 7</time_frame>
    <description>MAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>0-28 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Requiring Intubation and Mechanical Ventilation</measure>
    <time_frame>0-28 days</time_frame>
    <description>Intubation / Mechanical Ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths During Hospitalization</measure>
    <time_frame>Deaths during hospitalization (up to 3 months)</time_frame>
    <description>Hospital Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration Determined 15 Min After Inhalation and Trough Determined 4 Hours Following the Drug/Placebo Administration</measure>
    <time_frame>Day 3</time_frame>
    <description>Treprostinil Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days From Study Enrollment Until Mechanical Ventilation is Required</measure>
    <time_frame>Day 0 to day 28</time_frame>
    <description>Time to intubation and mechanical ventilation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>Treprostinil inhalation solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration will be administered as above for the active arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treprostinil Inhalation Solution</intervention_name>
    <description>Treprostinil inhalation solution administered as blinded marketed product</description>
    <arm_group_label>Treprostinil inhalation solution</arm_group_label>
    <other_name>TYVASO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sterile saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults age 18-75 years.

          2. Acute onset need for 4 liters per minute (LPM) or more of supplemental oxygen to
             maintain Arterial partial pressure of oxygen (PaO2) &gt; 60 mmHg or arterial O2
             saturation &gt; 90% by pulse oximetry.

          3. Acute unilateral pulmonary infiltrate/s on chest radiograph with no clinical evidence
             of left-sided heart failure. Bilateral infiltrates are acceptable as long as all other
             inclusion/exclusion criteria are met.

        Exclusion Criteria:

          1. No consent/inability to obtain consent

          2. Presence of pulmonary embolism

          3. Known diffuse alveolar hemorrhage from vasculitis

          4. Known pre-existing severe obstructive or restrictive lung disease (FEV 1 &lt; 40%
             predicted, total lung capacity (TLC) &lt; 50 % predicted) or need for long-term
             supplemental oxygen therapy

          5. Known significant left ventricular systolic dysfunction with left ventricular ejection
             fraction (LVEF) &lt; 45% on echocardiogram.

          6. Mean arterial pressure &lt; 65 mmHg

          7. Need for norepinephrine or dopamine dose &gt; 12 mcg to maintain mean arterial pressure
             (MAP) &gt; 65 mmHg

          8. Severe chronic liver disease (Child-Pugh Score 11-15)

          9. Moribund patient not expected to survive 24 hours

         10. Corrected QT interval (QTc) interval &gt; 500 ms on screening electrocardiogram

         11. Pregnancy or breast feeding (Women of childbearing potential, defined as &lt; 60 years of
             age, will require pregnancy testing.)

         12. Burns &gt; 40% total body surface

         13. Acute Neurological Disease (that may impair the ability to ventilate without
             assistance)

         14. Imminent need for intubation or non-invasive ventilation

         15. Patient is Do Not Resuscitate/Do Not Intubate

         16. Patient has a tracheotomy

         17. Patient is currently receiving prostacyclin therapy [Epoprostenol (Flolan or Veletri),
             Iloprost (Ventavis), Treprostinil (Orenitram, oral) (Remodulin, IV or SC)]

         18. Patient has a language barrier
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert J Ford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shannon Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne H Anderson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zwissler B, Kemming G, Habler O, Kleen M, Merkel M, Haller M, Briegel J, Welte M, Peter K. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1671-7.</citation>
    <PMID>8970353</PMID>
  </reference>
  <reference>
    <citation>Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996 Mar;153(3):991-6.</citation>
    <PMID>8630585</PMID>
  </reference>
  <reference>
    <citation>Walmrath D, Schneider T, Pilch J, Schermuly R, Grimminger F, Seeger W. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):724-30.</citation>
    <PMID>7881662</PMID>
  </reference>
  <reference>
    <citation>Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med. 2001 Jan;29(1):57-62.</citation>
    <PMID>11176161</PMID>
  </reference>
  <reference>
    <citation>Dahlem P, van Aalderen WM, de Neef M, Dijkgraaf MG, Bos AP. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med. 2004 Apr;32(4):1055-60.</citation>
    <PMID>15071401</PMID>
  </reference>
  <reference>
    <citation>Dorris SL, Peebles RS Jr. PGI2 as a regulator of inflammatory diseases. Mediators Inflamm. 2012;2012:926968. doi: 10.1155/2012/926968. Epub 2012 Jul 18. Review.</citation>
    <PMID>22851816</PMID>
  </reference>
  <reference>
    <citation>Raychaudhuri B, Malur A, Bonfield TL, Abraham S, Schilz RJ, Farver CF, Kavuru MS, Arroliga AC, Thomassen MJ. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J Biol Chem. 2002 Sep 6;277(36):33344-8. Epub 2002 Jun 24.</citation>
    <PMID>12082102</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <results_first_submitted>August 9, 2019</results_first_submitted>
  <results_first_submitted_qc>September 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Acute Lung Injury</keyword>
  <keyword>Acute Respiratory Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>only summary data via publication/abstract</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02370095/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One patient was consented, randomized (Placebo) and baseline data was collected. However, before receiving treatment the subject deteriorated, and a protocol defined stopping rule was met. The subject was defined as completed. Baseline data were used in the analyses, and the AEs recorded are presented in the AE section.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treprostinil Inhalation Solution</title>
          <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who signed a consent are included in baseline measurements</population>
      <group_list>
        <group group_id="B1">
          <title>Treprostinil Inhalation Solution</title>
          <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="13.1"/>
                    <measurement group_id="B2" value="51.8" spread="7.6"/>
                    <measurement group_id="B3" value="50.0" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Ratio of the Partial Pressure of Arterial Oxygen to the Fraction of Inspired Oxygen (PaO2/FiO2 Ratio)</title>
        <description>PaO2/FiO2 ratio</description>
        <time_frame>Change in PaO2/FiO2 ratio from day 0 to day 2.</time_frame>
        <population>Determination of this endpoint was dependent on subject consent for collection of an arterial blood sample. A baseline measure was obtained from thirteen subjects. Samples were obtained from seven subjects at day 2, and two subjects at day 7 and none at day 28. Analysis was limited to change from baseline to day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Ratio of the Partial Pressure of Arterial Oxygen to the Fraction of Inspired Oxygen (PaO2/FiO2 Ratio)</title>
          <description>PaO2/FiO2 ratio</description>
          <population>Determination of this endpoint was dependent on subject consent for collection of an arterial blood sample. A baseline measure was obtained from thirteen subjects. Samples were obtained from seven subjects at day 2, and two subjects at day 7 and none at day 28. Analysis was limited to change from baseline to day 2.</population>
          <units>P/F ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" spread="31.2"/>
                    <measurement group_id="O2" value="161.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Only one placebo subject had data to allow for change from baseline to be calculated</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2416</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Ratio of Peripheral Oxygen Saturation to Fraction of Inspired Oxygen (SaO2/FiO2)</title>
        <description>SaO2/FiO2</description>
        <time_frame>0-12 days</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Ratio of Peripheral Oxygen Saturation to Fraction of Inspired Oxygen (SaO2/FiO2)</title>
          <description>SaO2/FiO2</description>
          <population>Intent to treat</population>
          <units>S/F ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303.7" spread="22.0"/>
                    <measurement group_id="O2" value="382.3" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>The change in S/F ratio over time was evaluated using a mixed model for repeated measures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Not on a Ventilator</title>
        <description>Ventilator-free days</description>
        <time_frame>0-28 days post enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Not on a Ventilator</title>
          <description>Ventilator-free days</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="14.1"/>
                    <measurement group_id="O2" value="28" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0679</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Required Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) Via Face Mask</title>
        <description>BiPAP / CPAP</description>
        <time_frame>0-28 days</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Required Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) Via Face Mask</title>
          <description>BiPAP / CPAP</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Respiratory Distress Syndrome (ARDS) Associated Biomarkers</title>
        <description>Change in ARDS associated plasma biomarkers</description>
        <time_frame>Change from day 0 on days 3 and 7</time_frame>
        <population>Too few samples were collected at the designated days 3 and 7 to provide informative data. Plasma samples were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Respiratory Distress Syndrome (ARDS) Associated Biomarkers</title>
          <description>Change in ARDS associated plasma biomarkers</description>
          <population>Too few samples were collected at the designated days 3 and 7 to provide informative data. Plasma samples were not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Central Venous Oxygen Saturation (SCVO2).</title>
        <description>SCVO2</description>
        <time_frame>Change in SCVO2 from Day 0 to 3 (if central venous catheter in place)</time_frame>
        <population>None of the patients had a central venous line, so no samples were obtained for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Central Venous Oxygen Saturation (SCVO2).</title>
          <description>SCVO2</description>
          <population>None of the patients had a central venous line, so no samples were obtained for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Venous Pressure (CVP).</title>
        <description>CVP</description>
        <time_frame>Change in CVP from Day 0 to 3 (if central venous catheter in place)</time_frame>
        <population>A central venous line was not in place for the subjects so measurements could not be obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Venous Pressure (CVP).</title>
          <description>CVP</description>
          <population>A central venous line was not in place for the subjects so measurements could not be obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Arterial Pressure (MAP).</title>
        <description>MAP</description>
        <time_frame>Change in MAP from Day 0 to day 7</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Arterial Pressure (MAP).</title>
          <description>MAP</description>
          <population>Intent to Treat</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.96" spread="15.5"/>
                    <measurement group_id="O2" value="8.18" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Measurement of MAP were evaluated from baseline to end of treatment</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>All-cause mortality</description>
        <time_frame>0-28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>All-cause mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2507</p_value>
            <p_value_desc>The threshold for statistical significance was 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Requiring Intubation and Mechanical Ventilation</title>
        <description>Intubation / Mechanical Ventilation</description>
        <time_frame>0-28 days</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Requiring Intubation and Mechanical Ventilation</title>
          <description>Intubation / Mechanical Ventilation</description>
          <population>Intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths During Hospitalization</title>
        <description>Hospital Mortality</description>
        <time_frame>Deaths during hospitalization (up to 3 months)</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths During Hospitalization</title>
          <description>Hospital Mortality</description>
          <population>Intent to Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5055</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration Determined 15 Min After Inhalation and Trough Determined 4 Hours Following the Drug/Placebo Administration</title>
        <description>Treprostinil Plasma Concentration</description>
        <time_frame>Day 3</time_frame>
        <population>Only 3 plasma pharmacokinetic samples were collected from subjects treated with Treprostinil and therefore no measurements of plasma Treprostinil were made.</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration Determined 15 Min After Inhalation and Trough Determined 4 Hours Following the Drug/Placebo Administration</title>
          <description>Treprostinil Plasma Concentration</description>
          <population>Only 3 plasma pharmacokinetic samples were collected from subjects treated with Treprostinil and therefore no measurements of plasma Treprostinil were made.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days From Study Enrollment Until Mechanical Ventilation is Required</title>
        <description>Time to intubation and mechanical ventilation</description>
        <time_frame>Day 0 to day 28</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Treprostinil Inhalation Solution</title>
            <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days From Study Enrollment Until Mechanical Ventilation is Required</title>
          <description>Time to intubation and mechanical ventilation</description>
          <population>Intent to Treat</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of enrollment until end of follow-up, approximately 28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treprostinil Inhalation Solution</title>
          <description>Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
Treprostinil Inhalation Solution: Treprostinil inhalation solution administered as blinded marketed product</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo administration will be administered as above for the active arm
Placebo: Supplied by the manufacturer and similar to the active drug but containing no Treprostinil</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Emesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Elevated Transaminase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep Interference</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Retro-peritoneal hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Metapneumovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumomediatinum/Bilateral pneumothoraces</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Parapneuomonic Effusion with decortication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was stopped because of low recruitment. The limited number of subjects make it difficult to draw conclusions regarding the efficacy of Treprostinil in subjects at high risk of developing ARDS.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Wayne H Anderson, PhD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-445-0351</phone>
      <email>wayne_anderson@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

